Steroid receptors aplenty in prostate cancer.
Sharifi N. • 2014 • N Engl J Med. 2014;370(10):970-1.
© 2024 Corcept Therapeutics, Incorporated
“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R. • 2011 • Semin Oncol. 2011;38(2):254-62.
Minireview: nuclear receptors and breast cancer.
Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.
The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT • 1999 • Urol Clin North Am. 1999;26(2):263-73.
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Stringer-Reasor et al. • 2015 • Gynecol Oncol. 2015;138(3):656-62.
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay et al. • 2014 • Horm Cancer. 2014;5(2):72-89.
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Skor et al. • 2013 • Clin Cancer Res. 2013;19(22):6163-72.
Mifepristone inhibits GRβ coupled prostate cancer cell proliferation.
Ligr et al. • 2012 • J Urol. 2012;188(3):981-8.
Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.
Tieszen et al. • 2011 • BMC Cancer. 2011;11:207.
Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer.
Yan et al. • 2008 • Urol Int. 2008;81(2):228-33.